InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF – Get Free Report) traded down 3.6% on Tuesday . The stock traded as low as $0.26 and last traded at $0.26. 9,485,323 shares traded hands during trading, an increase of 83,331% from the average session volume of 11,369 shares. The stock had previously closed at $0.27.
InMed Pharmaceuticals Stock Performance
The company has a 50-day moving average of $0.27 and a two-hundred day moving average of $0.32.
InMed Pharmaceuticals Company Profile
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain.
Featured Stories
- Five stocks we like better than InMed Pharmaceuticals
- What is a Low P/E Ratio and What Does it Tell Investors?
- ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Leading Beverage Company’s Stock Bubbles Higher: Rally Ahead
- The 3 Best Retail Stocks to Shop for in August
- Can This Meme Stock Stage One Last Rally?
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
